It's been a nice week for the rebounding markets. Here's a few stocks to watch as the week goes on...
Immunocellular Therapeutics (IMUC.OB): Shares of Immunocellular Therapeutics (IMUC) have been on the fly since the opening days of 2012, even having tripled at one point before settling down to a trading range of just below the three dollar mark.
With numerous catalysts still pending this year, including a possible move to the AMEX and the presentation of interim results for the ongoing ICT-107 trial - which could come as early as late 2012 - this is still a company and a stock to watch.
According to a PR from the company released a couple of months ago, full enrollment for the trial is expected to reached within the current quarter and an interim analysis will be conducted "when 50% of events (32 deaths) have been observed."
Additionally, last month an announcement hit the wires that Immunocellular had established a second manufacturing site for ICT-107, which allows the company to increase production and meet the demands of the compound for the ongoing Phase II trial, but also positions the company for success should ICT-107 make it to Phase III, which looks ever more likely with each update provided by the company.
Immunocellular, as well as other developing companies in the cancer immunotherapy field, could expect to receive a speculative boost around the time of the ASCO conference, as well, which this year is scheduled for June 1-5 in Chicago.
With such catalysts pending, it's likely that IMUC could withstand any effects of a broad market sell off, were one to develop, especially with the company's technology gaining notoriety in the field of cancer immunotherapy.
Implant Sciences (OTC:IMSC): Shares of Implant Sciences (OTC:IMSC) have been gaining increasing attention as the company's hot stock has moved quickly from the sixty cent range to a dollar in quick time. It was also tough to ignore the company's technology over the weekend as stories circulated about US President Barak Obama's security team being sent home from the Summit of the Americas conference - held in Cartagena, Colombia - for enjoying just a little too much of the night life.
Such attention to the summit could also bring attention to the fact that Implant's narcotics and explosives detection technology was selected by the Colombian Security Forces as part of a layered defense plan to protect the various Heads-of-State from the Americas that attended the conference.
Given Colombia's constantly-increased state of security, thanks to the ongoing threat of attacks by the Revolutionary Armed Forces of Colombia (known as the FARC for its Spanish-language acronym), the selection of Implant's Quantum Sniffer technology for this event is a testament to its applicability in the growing global security scene.
Recent hirings at the company also foretell a potential increase in production and distribution, which could be a reason why IMSC is inching back towards the dollar mark after having retreated following a quick price run.
BioDelivery Sciences (BDSI): Shares of BioDelivery Sciences (BDSI) were on the move early this week after the announcement that the awarding of a key patent sparked a $15 million milestone payment by partner Endo Pharmaceuticals (ENDP), bringing the total milestone money already paid to BioDelivery by Endo to $45 million.
That is not an insignificant amount for a developing company such as BDSI, hence the immediate - and significant - boost in share price. The patent effectively extends the protection of BioDelivery's BioErodible MucoAdhesive (BEMA) technology by seven years.
BioDelivery is a company right back in the spotlight. The REMS resolution of its flagship product that treats breakthrough pain in cancer patients, Onsolis, could lead to a swift increase in near-term revenue to supplement the milestone payments, while recent legal developments also have worked out in the favor of BDSI.
BDSI is another one that has already tripled this year, and as such is a still a key stock to watch.
Capstone Turbine (CPST): After sinking to below the dollar mark over the past weeks, Capstone Turbine (CPST) is again providing evidence that the company is going to play a key role in fueling the future.
At the opening of this week's trading week, the company announced that it had expanded its presence in the hospital market with the sale of a C1000 Power Package to a Michigan hospital that will operate in a combined heat and power (CHP) application. The unit will provide backup and prime power for the hospital and is another demonstration of the broad scope of commercial applications that can be applied with Capstone's low-emission microturbine units.
As a follow-up to that order, the company then announced on Tuesday that it had secured an order for 30 more of its C65 units, which adds to the company's already robust presence in the Eagle Ford Shale Play.
In response to another order destined for the Eagle Ford Shale market, Sam Henry of Horizon Power stated:
"These multiple follow-on orders indicate that Capstone microturbines are quickly becoming the chosen power system to meet growing needs of major oil & gas producers operating in the Eagle Ford Shale Play. This order, along with the recent 10 MW order for C1000 Series products, proves we are making serious inroads in meeting the customer's high-caliber power needs with Capstone innovative technology."
Horizon Power Systems is Capstone's distributor in the region. The large order adds to the company's backlog and is a continued demonstration of the in-roads that Capstone is making in the green energy market. Shares spiked back to over a buck on the news.
Capstone also has an intriguing alliance with General Electric (GE) that is worth noting.
VFC's Stock House has been compensated by a third party, The ProActive Network, to provide research and coverage of Premier Alliance Group (OTCQB:PIMO) for a period of thirty days. The goal of VFC's Stock House is to bring new ideas, companies and discussions to investors and readers. With respect to the increased amount of time necessary to maintain quality, VFC's Stock House is at times compensated from third parties to research and cover certain companies that fit the profile of what interests the readers of VFC's Stock House. While taking compensation poses as an inherent perception of bias in coverage, the ultimate goal is to bring ideas and information to the eyes of readers, who can then decide what is and what is not relevant.
Premier Alliance Group (OTCQB:PIMO): Premier Alliance Group (OTCQB:PIMO) is another company capitalizing on the shifting energy needs of big business and government agencies, although in a different manner. Premier provides advisory and consulting services to a broad scope of customers and its GreenHouse division has recently secured multiple significant orders from municipalities and government agencies to conduct energy audits and enable these entities to meet the federal guidelines that are ever-changing.
Additionally, in a time when energy costs are growing along with the increased regulation from the State and Federal levels, Premier has assisted its customers in shaving those costs while maintaining the standards that fit its customer's needs.
The company has a growing presence in Southern California where it has become a recognized expert of helping businesses and local governments apply Southern California Edison's (SCE) Automated Demand Response (Auto-DR) program, which has led to numerous tax and energy-saving incentives for those entities.
Volume has been light for PIMO, aside from a March spurt that accompanied a slew of press releases announcing new deals, but as Premier's business continues to expand, interest in the stock could lead to a steady influx of volume, which in turn could lead to a spike in share price.
Synergy Pharmaceuticals (SGYP): Synergy Pharmaceuticals (SGYP) is going to be a stock to watch over the short term, but especially for the duration of 2012 and into 2013 as significant price increases are possible.
Synergy has developed a treatment for chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C), both multi-billion dollar markets, which when/if approved, will provide superior performance to its competition on the market, if the results of already-concluded trials hold consistent through late stage trials.
While Synergy's treatment is able to normalize the effects of both CIC and IBS-C, already-concluded trials indicate that the competition also helps to cure the effects of constipation, but actually reverses the nuance and turns it into diarrhea. Common sense would indicate that Synergy's product would, in turn, become the treatment of choice.
With that in mind, it's not out of the question to believe that Synergy is positioned to approach the billion dollar-plus market cap of the competition, Ironwood Pharmaceuticals (IRWD), which is further along in the development of its product, but as discussed, may not hold the superior technology.
Keep and eye on this one, as quite a few analysts are starting to come on board with 'Buy' ratings.
Volume in Celsius Holdings (OTC:CELH) has spiked during early trading this week. Having signed another PR firm recently, it could be time for this company's products to hit the mainstream again...Dendreon Corp (DNDN) quickly back to trading for over nine bucks after slipping below that mark during the market pullback last week...Human Genome Sciences (HGSI) again starting to receive positive media coverage, and could be a decent buy at current levels...Agenus Inc (AGEN) slipping, but positive trial data expected. Happy Trading.
Disclosure: Long IMUC, IMSC, CPST, PIMO, SGYP, CELH.